Results 11 to 20 of about 15,404 (212)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Diabetes, Metabolic Syndrome and Obesity, 2010
Bo AhrénDepartment of Clinical Sciences, Lund University, Lund, SwedenAbstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike peptide-1 (GLP-1). This increases circulating levels of active GLP-1, stimulates
Ahren B
doaj   +3 more sources

Hypoglycemia associated with off-label sitagliptin use

International Medical Case Reports Journal, 2008
Heather P Whitley1,2, Kristi Kelley11Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Auburn, AL, USA; 2Department of Community and Rural Medicine, University of Alabama School of Medicine, Tuscaloosa, AL, USAPurpose: To ...
Heather P Whitley, Kristi Kelley
doaj   +1 more source

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2009
Jonathan K ReynoldsWashington State University, College of Pharmacy, Pullman, WA, USAAbstract: JanumetTM, a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval ...
Jonathan K Reynolds
doaj   +1 more source

Sitagliptin, Metformin and Glimepiride Fixed-Dose Combination Compared to Co-Administration of Metformin and High-Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double-Blind, Double-Dummy, Phase 3 Clinical Study. [PDF]

Diabetes Obes Metab
ABSTRACT Aims This study assessed the efficacy and safety of a triple fixed‐dose combination (FDC) of sitagliptin, metformin, and glimepiride versus co‐administered metformin and glimepiride in Indian patients with uncontrolled Type 2 diabetes (T2D).
Sahay R, Gowda A, Singh MK, Rao AG, Duraisamy R, Gangwani D, Shukla J, Agarwal V, Patil SS, C A, K N SB, Palawat A, Gofne SK, Sahoo AK, Rai PK, Shaikh R, Saha S, Patil D, Ghadge P, Patel P, Lakhwani L, Mehta S, Joglekar S.   +22 more
europepmc   +2 more sources

Attenuation of acrylamide-induced neurotoxicity by supplementation of sitagliptin in Wistar rats [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): Acrylamide (ACR) induces neurotoxicity in humans and animals through different mechanisms. Sitagliptin is a type-2 diabetes medication with neuroprotective properties.
Mahboobeh Navabi, Mahboobeh Ghasemzadeh Rahbardar, Soghra Mehri, Hossein Hosseinzadeh   +3 more
doaj   +1 more source

Sitagliptin Stimulates Endothelial Progenitor Cells to Induce Endothelialization in Aneurysm Necks Through the SDF-1/CXCR4/NRF2 Signaling Pathway

Frontiers in Endocrinology, 2019
Aneurysm (AN) embolization is an important treatment for cerebral aneurysms. The endothelialization of the aneurysm neck is crucial for preventing aneurysm recurrence.
Guo Yu, Guo Yu, Peixi Liu, Peixi Liu, Yuan Shi, Yuan Shi, Sichen Li, Sichen Li, Yingjun Liu, Yingjun Liu, Wei Zhu, Wei Zhu   +11 more
doaj   +1 more source

Sitagliptin Induces Tolerogenic Human Dendritic Cells [PDF]

, 2023
Sitagliptin, an anti-diabetic drug, is a dipeptidyl peptidase (DPP)-4/CD26 inhibitor with additional anti-inflammatory and immunomodulatory properties. In this study, we investigated for the first time the effect of sitagliptin on the differentiation and
Đokić, Jelena, Dejan Bokonjić, Drakul, Marija, Popović, Nikola, Bokonjić, Dejan, Marina Bekić, Tomić, Sergej, Jelena Đokić, Miloš Vasiljević, Rakočević, Sara, Vasiljević, Miloš, Dušan Mihajlović, Nikola Popović, Marija Drakul, Miodrag Čolić, Bekić, Marina, Sergej Tomić, Mihajlović, Dušan, Sara Rakočević, Čolić, Miodrag   +19 more
core   +1 more source

PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness

BMJ Open Diabetes Research & Care, 2020
Introduction Sitagliptin is a dipeptidyl peptidase 4 inhibitor for the treatment of type 2 diabetes (T2D). Limited real-world data on its effectiveness and safety are available from an Italian population.Research design and methods We evaluated long-term
Antonio Carlo Bossi, Valentina De Mori, Carlotta Galeone, Davide Pietro Bertola, Margherita Gaiti, Annalisa Balini, Denise Berzi, Franco Forloni, Giancarla Meregalli, Federica Turati   +9 more
doaj   +1 more source

SITAGLIPTIN; SITAGLIPTIN AS ADD ON THERAPY TO PATIENTS ON INSULIN.

The Professional Medical Journal, 2017
The objective of this stidy is to compare the mean reduction of HbA1c in patientstaking sitagliptin insulin combination with insulin alone in patients of type II Diabetes mellitus.Study Design: Randomized control trial (RCT). Setting: Medicine Department, Allied Hospital,Faisalabad. Period: August 2013 to February 2014.
Zaheer Ahmed, Hassan Fareed, Muhammad Usman Musharraf   +2 more
openaire   +2 more sources

Significance of Vascular Dipeptidyl Peptidase-4 Inhibition on Vascular Protection in Zucker Diabetic Fatty Rats

Journal of Pharmacological Sciences, 2014
.: To clarify the role of dipeptidyl peptidase-4 (DPP-4) inhibition in vascular tissues, we compared the effects of the poorly tissue-penetrative DPP-4 inhibitor sitagliptin to the highly tissue-penetrative DPP-4 inhibitor linagliptin in Zucker diabetic ...
Shinji Takai, Hiroshi Sakonjo, Denan Jin
doaj   +1 more source